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Here, we assessed whether 41 SNPs within steroid hormone genes associated with erosive disease. 
The most relevant finding was the rheumatoid factor (RF)-specific effect of the CYP1B1, CYP2C9, ESR2, 
FcγR3A, and SHBG SNPs to modulate the risk of bone erosions (P = 0.004, 0.0007, 0.0002, 0.013 and 
0.015) that was confirmed through meta-analysis of our data with those from the DREAM registry 
(P = 0.000081, 0.0022, 0.00074, 0.0067 and 0.0087, respectively). Mechanistically, we also found a 
gender-specific correlation of the CYP2C9rs1799853T/T genotype with serum vitamin D3 levels (P = 0.00085) 
and a modest effect on IL1β levels after stimulation of PBMCs or blood with LPS and PHA (P = 0.0057 
and P = 0.0058). An overall haplotype analysis also showed an association of 3 ESR1 haplotypes with 
a reduced risk of erosive arthritis (P = 0.009, P = 0.002, and P = 0.002). Furthermore, we observed 
that the ESR2, ESR1 and FcγR3A SNPs influenced the immune response after stimulation of PBMCs or 
macrophages with LPS or Pam3Cys (P = 0.002, 0.0008, 0.0011 and 1.97•10−7). Finally, we found that a 
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model built with steroid hormone-related SNPs significantly improved the prediction of erosive disease 
in seropositive patients (PRf+ = 2.46•10−8) whereas no prediction was detected in seronegative patients 
(PRf− = 0.36). Although the predictive ability of the model was substantially lower in the replication 
population (PRf+ = 0.014), we could confirm that CYP1B1 and CYP2C9 Snps help to predict erosive 
disease in seropositive patients. These results are the first to suggest a RF-specific association of steroid 
hormone-related polymorphisms with erosive disease.
Rheumatoid arthritis (RA) is a chronic and disabling chronic immune-mediated inflammatory disease that 
affects approximately 1% of the worldwide population1. Although the etiology of this autoimmune disease 
remains largely unknown, family- and population-based genome-wide association studies (GWAS) have con-
sistently demonstrated that RA has a strong inherited component that influences not only the predisposition to 
develop the disease2–5. Even though there are no relevant predictors for treatment response in RA6, recent studies 
have suggested that inherited genetic factors might influence the response to both classical disease-modifying 
anti-rheumatic or biological drugs7–11 and even disease progression12–14. From epidemiological studies, it has also 
been proposed that in addition to inherited factors and environmental factors certain hormonal events might help 
to promote the onset of the disease15–17. It has been suggested that concentrations of steroid hormones and circu-
lating immunocomplexes (CICs) in the synovial fluid and cartilage may contribute to promote gender-specific 
inflammatory responses, a differently controlled and sustained production of autoantibodies between men and 
women18–20 and a different release of a wide range of cytokines and pro-inflammatory mediators that trigger 
sustained and chronic inflammatory responses21–23. However, there is still controversy about the effect of steroid 
hormones on the risk of developing RA or disease progression since the administration of different hormone 
replacement therapies or the use of oral contraceptives has not been associated with the risk of RA and its pro-
gression in most of the epidemiological studies conducted to date24–27.
Some authors have hypothesized that these controversial results might be, at least in part, due to the pres-
ence of certain factors such as the HLA-DRB1 shared epitope or specific autoantibodies such as antibodies to 
cyclic citrullinated peptide (anti-CCP)28,29. Furthermore, there are contradictory results concerning to the role 
of steroid hormones in the modulation of immune responses. Some studies have reported, for instance, that 
vitamin D3 has immunomodulatory properties that may influence autoimmune disease risk and disease pro-
gression30 whereas some other have suggested that estrogens can induce both tolerogenic and pro-inflammatory 
responses at multiple levels and that this may result in remarkable sex differences on immune function. Under 
appropriate circumstances, estrogens may inhibit Th1- and Th17-mediated immune functions31,32 and stimu-
late Treg cell development33 and the activation of Th2-mediated immune responses. However, it has been also 
demonstrated that estrogens may induce pro-inflammatory responses. For instance, it has been suggested that 
estrogens influence FcγR3A mRNA gene expression and induce the FcγR3A-mediated release of tumor necrosis 
factor (TNF) and IL1β from monocytes34, thereby modulating degranulation, antibody-dependent cellular cyto-
toxicity (ADCC), transcription of cytokine genes, rapid release of inflammatory mediators and reactive oxygen 
species, and phagocytosis35–37. Considering the role of FcγR proteins in modulating autoimmune responses but 
also the plausibility of a gender-specific effect of estrogens to modulate immune responses, we aimed at analyzing 
whether the presence of single nucleotide polymorphisms (SNPs) within steroid hormone signaling (ESR1, ESR2, 
NR1I2, PGR, and SHBG), phase I- and II-metabolizing enzyme (CYP1A1, CYP1A2, CYP1B1, CYP17A1, CYP2C9, 
CYP2C19, CYP3A4, GSTP1, HSD17B1 and SULT1A1) and Fc gamma receptor (FcγR3A and FCGR2A) genes 
influence disease progression in RA. We assessed whether 41 potentially functional SNPs within these genes are 
associated with the risk of developing erosive disease and whether the effect of the SNPs on disease progression 
was modified by the presence of rheumatoid factor (RF) or anti-CCP. In order to confirm the consistency of our 
results, we performed fixed-effect meta-analyses with data from the DREAM registry. Finally, we also evaluated 
whether selected polymorphisms correlated with steroid hormone and cytokine levels and whether genotyping of 
selected SNPs might help us to improve the prediction of the appearance of bone erosions.
patients and Methods
Study population. This retrospective cohort study included 816 RA patients ascertained through the 
REPAIR consortium (567 showing erosive disease and 249 without bone erosions). RA patients fulfilled the 
1987 revised American College of Rheumatology (ACR)38 and the ACR/EULAR 2010 classification criteria39. A 
detailed description of the population has been reported elsewhere40–42. Briefly, 518 RA patients were recruited at 
the department of Rheumatology of the Virgen de las Nieves Hospital (Granada, Spain), the Reina Sofia Hospital 
(Córdoba, Spain), and the University Clinical Hospital of Santiago de Compostela (Santiago de Compostela, 
Spain). Two hundred and ninety-eight RA patients were additionally recruited from the Santa Maria Hospital–
CHLN (Biobanco-IMM; Lisbon Academic Medical Centre, Lisbon, Portugal). The study was performed accord-
ing to the Helsinki Declaration. All participants were of European ancestry and gave their written informed 
consent to participate in the study. The Ethics committee of each participant institution approved the study 
protocol: Virgen de las Nieves University Hospital (2012/89); Santa Maria Hospital-CHLN (CE 877/121.2012); 
University Clinical Hospital of Santiago de Compostela (2013/156). A detailed description of demographic and 
clinical variables of this population is included in Table 1.
Bone erosions. Bone erosions were visible in plain radiographs and defined as the interruption of the cortical 
bone surface within the joint region or underlying the cartilage43,44. Bone erosions were then coded as present or 
absent. All radiographs were assessed by, at least, an experienced radiologist or rheumatologist.
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Snp selection and genotyping. We conducted an extensive literature search concerning the mecha-
nism of action of estrogen and progesterone receptor, hormone transporter, and hormone-metabolizing enzyme 
genes was performed to select candidate genes that might affect the risk of developing bone erosions. SNPs were 
assessed on the basis of NCBI data and were selected according to their known or putative functional conse-
quences, i.e. their modifying influence on the structure of proteins, transcription level, or alternative splicing 
mechanisms. SNPs within the same gene were also selected on the basis of linkage disequilibrium (LD) data. In 
total, 41 SNPs in 17 genes were selected for this study (Table 2).
Genotyping of selected steroid hormone-related SNPs was performed at GENYO (Granada, Spain) using 
KASPar® probes with the exception of the FcγR3Ars396991 and FCγR2Ars1801274 SNPs that were determined using 
TaqMan® SNP Genotyping Assays (Life Technologies, Carlsbad, CA, USA). Both KASPar® and Taqman® assays 
were assayed according to the manufacturer’s specifications for a 384-well plate format. Genomic DNA was 
extracted from peripheral blood mononuclear cells (PBMCs) using Qiagen Mini kit (Qiagen, Valencia, CA, USA) 
and PCR products were analyzed with ABI Prism 7900HT detection system using the SDS 2.4 software (Applied 
Biosystems). Five percent of samples were included in the PCR plates as duplicates and concordance between the 
analyzed original and duplicated samples was >99.0%.
Statistical analysis. Hardy-Weinberg Equilibrium (HWE) was assessed in the control group by a 
chi-square (χ2) test. Logistic regression analysis adjusted for age, sex and country of origin was used to assess 























Demographic characteristics (n = 816) (n = 567) (n = 249) (n = 436) (n = 307) (n = 129)
Age (years) 59.32 ± 13.11 59.66 ± 12.47 58.95 ± 14.30 0.50 53.59 ± 12.84 53.63 ± 10.17 53.47 ± 13.30 0.90
Sex ratio (female/male) 3.74 (644/172) 4.4 (462/105) 2.71 (182/67) 0.007 2.06 (294/143) 2.13 (209/98) 1.87 (84/45) 0.55
Clinical assessment
Percentage of patients with RF 
positivity* 571 (70.58) 409 (72.52) 162 (66.12) 0.07 328 (77.72) 235 (78.33) 93 (76.23) 0.64
Percentage of ACPA-positive 
patients* 490 (72.80) 354 (74.21) 136 (69.39) 0.20 90 (58.06) 64 (58.72) 26 (61.91) 0.72
DAS28 at baseline 5.63 ± 2.40 5.57 ± 1.18 5.79 ± 4.17 0.41 5.24 ± 1.27 5.27 ± 1.23 5.16 ± 1.36
Disease follow-up (years) 18.30 ± 9.34 19.43 ± 9.00 17.80 ± 14.44 0.10 9.00 ± 9.87 9.17 ± 10.17 8.58 ± 9.09
Percentage of RA patients having 
erosive disease 567 (69.49) 567 (100.0) 0 (0.0) — 307 (70.41) 307 (100.0) 0 (0.0) —
Percentage of RA patients with 
biologic treatments 632 (77.45) 448 (79.01) 184 (73.90) 0.11 436 (100.00) 307 (100.0) 129 (100.0) 1.00
DMARDs
Methotrexate∂ 603 (79.24) 415 (79.20) 188 (79.32) 0.97 314 (75.48) 226 (77.13) 88 (71.54) 0.23
First biological treatment
Infliximab (%) 271 (42.88) 221 (44.02) 50 (37.88) 0.25 106 (24.31) 79 (25.73) 27 (20.93) 0.29
Etanercept (%) 176 (27.85) 134 (26.69) 42 (32.30) 0.20 101 (23.16) 72 (23.45) 29 (22.48) 0.83
Adalimumab (%) 157 (24.84) 126 (25.10) 31 (23.85) 0.77 229 (52.52) 156 (50.81) 73 (56.59) 0.27
Golimumab (%) 11 (1.74) 7 (01.39) 4 (03.08) 0.19 — — — —
Abatacep (%) 5 (0.79) 4 (00.80) 1 (00.77) 0.98 — — — —
Tocilizumab (%) 4 (0.63) 2 (00.40) 2 (01.52) 0.14 — — — —
Rituximab (%) 8 (1.27) 8 (01.59) 0 (00.00) — — — — —
Table 1. Demographic and clinical characteristics of RA patients included in the discovery and replication 
cohorts. Data are means ± standard deviation or n (%). Abbreviations: RF, rheumatoid factor; ACPA: anti-
citrullinated protein antibodies; DAS28, disease activity score; DMARDs, disease-modifying anti-rheumatic 
drugs. P < 0.05 in bold. *RF and anti-CCP data were available in 809 and 673 RA patients in the discovery 
population, respectively. *RF and anti-CCP data were available in 564 and 477 RA patients with erosive disease 
in the discovery population, respectively. *RF and anti-CCP data were available in 245 and 196 RA patients 
without erosive disease in the discovery population, respectively *RF and anti-CCP data were available in 422 
and 151 RA patients in the replication population, respectively. *RF and anti-CCP data were available in 300 
and 109 RA patients with erosive disease in the replication population, respectively. *RF and anti-CCP data 
were available in 122 and 42 RA patients without erosive disease in the replication population, respectively. 
∂Information about methotrexate treatment was available in 761 and 416 patients in the discovery and 
replication populations, respectively. ∂Information about methotrexate treatment was available in 524 and 293 
patients with erosive disease in the discovery and replication populations, respectively. ∂Information about 
methotrexate treatment was available in 237 and 123 patients without erosive disease in the discovery and 
replication populations, respectively.
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anti-CCP-stratified analyses were also carried out and we included RF as interaction term in the overall logistic 
regression analysis to evaluate whether there was any statistically significant effect modification by these factors. 
Haplotype analysis using the same variables for adjustment was conducted using the R package Haplo.stats45. In 
order to facilitate eventual meta-analyses, the major allele was set as reference allele. All tests were conducted 
using the statistical software STATA (v.12) and R (http://www.r-project.org). In order to account for multiple test-
ing, we set a P value of 0.00074 as significance study-wide threshold. The P value was calculated considering the 
number of independent polymorphisms analyzed (n = 34, MeffLi method)46 but also the number of inheritance 
models tested (dominant and recessive).
Linkage disequilibrium (LD) and haplotype analysis. We performed haplotype frequency estimation 
and haplotype association analysis adjusted for age, sex and country of origin using the haplo.stats45. Haplotype 
frequencies were determined using the Expectation-maximization (EM) algorithm and haplotypes were recon-
structed using SNPtools47 and Haploview48. Block structures were determined according to the method of Gabriel 
et al.49 (Supplementary Fig. 1).







CYP1A1 15 rs1799814 A/C A T461N
CYP1A2 15 rs762551 A/C C intronic
CYP1B1 2 rs1800440 A/G G N453T
CYP1B1 2 rs1056836 C/G G L432V
CYP1B1 2 rs10012 C/G G R48G
CYP2C9 10 rs1799853 C/T T R144C
CYP2C9 10 rs1057910 A/C C I359L
CYP2C19 10 rs12248560 C/T T Near gene
CYP2C19 10 rs4244285 A/G A P227P
CYP3A4 7 rs2740574 A/G G Near gene
CYP3A4 7 rs11773597 C/G C Near gene
CYP17A1 10 rs743572 A/G G 5′-UTR
ESR1 6 rs851984 C/T T intronic
ESR1 6 rs2881766 G/T G intronic
ESR1 6 rs2071454 G/T G 5′-UTR
ESR1 6 rs2077647 A/G G S10S
ESR1 6 rs827421 C/T C intronic
ESR1 6 rs2234693 C/T C Intronic
ESR1 6 rs9340799 A/G G intronic
ESR1 6 rs1801132 C/G G P325P
ESR1 6 rs3798577 C/T C 3′-UTR
ESR1 6 rs910416 C/T T Near gene
ESR2 14 rs1255998 C/G G 3′-UTR
ESR2 14 rs928554 A/G G 3′-UTR
ESR2 14 rs4986938 T/C T 3′-UTR
ESR2 14 rs1271572 G/T T Near gene
FcγR2A 1 rs1801274 A/G G H131R
FcγR3A 1 rs396991 A/C C V158F
GSTP1 11 rs1695 A/G G I105V
GSTP1 11 rs1138272 C/T T A114V
HSD17B1 17 rs605059 C/T T G313S
NR1I2 3 rs2276706 A/G A Near gene
NR1I2 3 rs1464603 C/T C intronic
NR1I2 3 rs6785049 A/G G intronic
NR1I2 3 rs2276707 C/T T intronic
NR1I2 3 rs1054191 A/G A 3′-UTR
PGR 11 rs1042838 C/A A V660L
PGR 11 rs1379130 A/G A G393G
PGR 11 rs518162 A/G A 5′-UTR
SHBG 17 rs6259 A/G A D356N
SULT1A1 16 rs9282861 A/G A R213H
Table 2. Selected SNPs within steroid hormone-related genes. Abbreviations: SNP, single nucleotide 
polymorphism; MAF, minor allele frequency; UTR, untranslated region.
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Replication population and meta-analysis. With the aim of assessing the consistency of the overall 
and RF-specific associations between SNPs and the risk of developing bone erosions, we genotyped the most 
interesting markers in a replication population from the DREAM registry consisting of 436 RA patients (307 RA 
patients with bone erosions and 129 patients without erosive disease). Demographic and clinical parameters of 
this population are also included in Table 1. We performed a meta-analysis of the data obtained in the discovery 
population with those from the DREAM registry and we pooled the Odds Ratios (ORs) for the most interesting 
polymorphisms using a fixed-effect model. Coefficients with a P-value ≤ 0.05 were considered significant. I2 sta-
tistic was used to assess heterogeneity between studies.
functional analysis of the estrogen-related variants. Cytokine stimulation experiments were con-
ducted in the 500 Functional Genomics (500FG) cohort from the Human Functional Genomics Project (HFGP; 
http://www.humanfunctionalgenomics.org/), which was designed to determine the influence of genomic varia-
tion on the variability of immune responses. The HFGP study was approved by the Arnhem-Nijmegen Ethical 
Committee (no. 42561.091.12) and biological specimens were collected after informed consent was obtained. We 
investigate whether any of the 41 estrogen-related SNPs correlated with cytokine levels (IFNγ, IL1β, IL6, TNFα, 
IL17, and IL22) after the stimulation of peripheral blood mononuclear cells (PBMCs), macrophages or whole 
blood from 408 healthy subjects with LPS (1 or 100 ng/ml), PHA (10 μg/ml), and Pam3Cys (10 μg/ml). After 
log transformation, linear regression analyses adjusted for age and sex were used to determine the correlation of 
selected SNPs with cytokine expression quantitative trait loci (cQTLs). All analyses were performed using R soft-
ware (http://www.r-project.org/). In order to account for multiple comparisons, we used a significant threshold of 
0.00025 (0.05/34 independent SNPs × 6 cytokines).
Details on PBMCs isolation, macrophage differentiation and stimulation assays have been reported else-
where50–52. Briefly, PBMCs were washed twice in saline and suspended in medium (RPMI 1640) supplemented 
with gentamicin (10 mg/mL), L-glutamine (10 mM) and pyruvate (10 mM). PBMC stimulations were performed 
with 5 × 105 cells/well in round-bottom 96-wells plates (Greiner) for 24 hours in the presence of 10% human pool 
serum at 37 °C and 5% CO2. Supernatants were collected and stored in −20 °C until used for ELISA. LPS (100 ng/
ml), PHA (10 μg/ml) and Pam3Cys (10 μg/ml) were used as stimulators for 24 or 48 hours. Whole blood stimula-
tion experiments were conducted using 100 μl of heparin blood that was added to a 48 well plate and subsequently 
stimulated with 400 μl of LPS and PHA (final volume 500 ul) for 48 hours at 37 °C and 5% CO2. Supernatants were 
collected and stored in −20 °C until used for ELISA. Concentrations of human IFNγ, IL1β, IL6, TNFα, IL17, and 
IL22 were determined using specific commercial ELISA kits (PeliKine Compact, Amsterdam, or R&D Systems), 
in accordance with the manufacturer’s instructions.
Once we assessed the correlation of estrogen-related SNPs with cytokine levels, we used the HaploReg SNP 
annotation tool (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) to further investigate the 
functional consequences of each specific variant. We also assessed whether any of the potentially interesting 
markers correlated with mRNA expression levels of their respective genes using data from public eQTL browsers 
(GTex portal; www.gtexportal.org/home/ and Blood eQTL browser; https://genenetwork.nl/bloodeqtlbrowser/).
correlation between steroid hormone levels and hormone-related Snps. We also measured 
serum levels of seven steroid hormones (androstenedione, cortisol, 11-deoxy-cortisol, 17-hydroxy progesterone, 
progesterone, testosterone and 25 hydroxy vitamin D3) in the 500FG cohort, which includes 531 healthy subjects. 
Complete protocol details of steroid hormone measurements have been reported elsewhere52. Hormone levels 
and genotyping data were available for a total of 406 subjects.
After log-transform, correlation between steroid hormone levels and steroid hormone-related SNPs was eval-
uated by linear regression analysis adjusted for age and sex (or for age when men and women were analysed 
separately). In order to avoid a possible bias, we excluded from the analysis those subjects that were using oral 
contraceptives or those subjects in which this information was not available. A total of 279 healthy subjects (107 
women and 272 men) were finally available for analysis. Significance threshold was set to 0.00021 considering the 
number of independent SNPs tested (n = 34) and the number of hormones determined (n = 7).
predictive models and discriminative accuracy. The value of steroid hormone-related variants for pre-
diction of prognosis and disease progression in seropositive and seronegative RA patients was assessed using 
stepwise logistic regression. Models were built including demographic variables (age and sex) and genetic poly-
morphisms that showed significant associations with erosive disease in the single-SNP analysis (P < 0.05). The 
genetic model was then compared with the reference model including demographic variables. The area under 
the curve (AUC) of a receiver operating characteristic (ROC) curve analysis and −2 log likelihood ratio (LR) 
tests were used to assess whether the genetic models fitted significantly better the data compared to their respec-
tive reference models. Finally, we run randomization tests to confirm whether the improved predictive ability 
of each genetic model was consistent after 50.000 iterations. All tests were conducted using R software (http://
www.r-project.org/).
ethics approval. The study was approved by the ethical review committee of each participant institution 
(Virgen de las Nieves University Hospital, Granada, Spain; Reina Sofia Hospital, Córdoba, Spain; University 
Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain; Biobanco-IMM, Lisbon Academic 
Medical Centre, Portugal. Cytokine stimulation experiments and hormone analysis were approved by the 
Arnhem-Nijmegen Ethical Committee.
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Results
Erosive RA patients had a similar age than those patients without bone erosions (59.66 ± 12.47 vs. 58.95 ± 14.30, 
P = 0.50) and had a significantly higher female to male ratio (462/105 = 4.4 vs. 182/67 = 2.71, P = 0.007; Table 1). 
Overall, the percentage of RA patients with positive RF and anti-CCP was 70.58% and 72.80% respectively, and 
these percentages were slightly higher among those patients with bone erosions (72.52% and 74.21%) than in 
those without erosive disease (66.12% and 69.39%). The mean of disease follow-up was 18.30 years whereas 
the mean of DAS28 was 5.63. Six hundred and three patients received methotrexate (79.24%) and 632 patients 
(77.45%) were treated with biologic therapies. With the exception of gender, none of the demographical or clini-
cal variables significantly differ between patient with and without erosive disease (Table 1).
Association of steroid hormone-related polymorphisms with the risk of having bone ero-
sions. Selected polymorphisms did not show deviation from HWE in the control population (patients without 
erosive disease; P > 0.001). Logistic regression analysis adjusted for age, gender and country of origin revealed 
that carriers of the ESR2rs1271572T/T genotype tended to have a decreased risk of developing erosive disease than 
those subjects carrying the G allele (OR = 0.55, P = 0.004: Table 3). Although the association of the ESR2rs1271572T/T 
genotype with a decreased risk of having bone erosions remained only marginally significant after correction 
for multiple testing, we found a significant RF-specific effect of this SNP to modulate the risk of having erosive 
disease. Seropositive patients carrying the ESR2rs1271572T/T genotype had a significantly reduced risk of developing 
erosive disease (OR = 0.38, P = 0.0002) whereas an opposite but not significant effect was found in seronegative 
patients (OR = 1.08, P = 0.83; PInt = 0.018; Table 3). Importantly, the association of the ESR2rs1271572 SNP with a 
reduced risk of developing bone erosions in seropositive patients remained significant after correction for multi-
ple testing (P < 0.00074). Although the association was not replicated in the DREAM cohort, the meta-analysis 
of our data and those from the DREAM registry, including 1252 RA patients, confirmed that seropositive 
patients carrying the ESR2rs1271572T/T genotype had a decreased risk of developing erosive disease (ORRF+ = 0.52, 
P = 0.00074) whereas a totally opposite but not statistically significant effect was found in seronegative patients 
(ORRF− = 1.28, P = 0.42; PHet = 0.33; Table 4). No significant anti-CCP effect modification was found for this SNP 
to modulate the risk of developing bone erosions (PInt = 0.11; Supplementary Table 1), which suggest that ESR2 
locus might play a relevant role in determining disease progression in a RF-dependent manner. In agreement with 
these results, we found a RF-specific effect of the ESR2CGTA haplotype to determine the risk of developing erosive 
disease. Seropositive RA patients carrying the ESR2CGTA haplotype (and, therefore, not harboring the ESR2rs1271572 
protective allele) showed an increased risk of developing bone erosions (ORRF+ = 1.63, P = 0.0051) whereas an 
opposite but not significant effect was detected in seronegative patients (ORRF− = 0.93, P = 0.99; Supplementary 
Table 2). An overall haplotype analysis including 1252 RA patients from the discovery and replication popula-
tions confirmed the RF-specific association of the ESR2CGTA haplotype with an increased risk of developing bone 
erosions (ORRF+ = 1.44, 95%CI 1.13–1.84; P = 0.0036 and ORRF− = 0.89, 95%CI 0.62–1.26; P = 0.51). According 
to publicly available gene expression datasets (GTex portal and Haploreg), the ESR2rs1271572 variant strongly cor-
relate with ESR2 mRNA expression levels in whole peripheral blood (P = 3.1•10−9) but also in primary B cells, 
lymphoblastoid cell lines (from P = 1.98•10−6 to P = 3.47•10−10) and several tissues (ranging from P = 2.60•10−5 
to P = 8.33•10−23; Supplementary Table 3). Intriguingly, a similar level of correlation with gene expression was 
found for other variants belonging to the ESR2CGTA haplotype (Supplementary Table 3), which strongly suggested 
that the ESR2rs1271572 SNP or ESR2CGTA haplotype might represent an eQTL for ESR2.
Similarly, we also found a RF-specific effect of the CYP2C9rs1799853 and CYP1B1rs10012 SNPs to determine the 
risk of developing bone erosions. Seropositive patients carrying the CYP2C9rs1799853T/T or CYP1B1rs10012G/G gen-
otypes had a significantly reduced chance of developing bone erosions (OR = 0.16, P = 0.0007 and OR = 0.42, 
P = 0.0040) whereas an opposite but not significant effect was observed in seronegative patients (OR = 2.71, 
P = 0.23; PInt = 0.003 and OR = 1.70, P = 0.35; PInt = 0.031; Table 3). The effect of the CYP2C9rs1799853 polymor-
phism on the risk of developing erosive disease in seropositive patients remained statistically significant after 
correction for multiple testing (P < 0.00074), which suggested a role of the CYP2C9 gene in modulating disease 
progression in RA. In accordance with these findings, we found that seropositive patients carrying the CYP2C9AT 
haplotype had a significantly decreased risk of developing erosive disease (ORRF+ = 0.61, P = 0.0075) whereas 
no effect was observed in seronegative patients (ORRF− = 0.87, P = 0.57; Supplementary Table 2). No significant 
anti-CCP effect modification was found for CYP2C9 and CYP1B1 variants to determine the appearance of bone 
erosions (PInt = 0.88 and PInt = 0.27) underlying the importance of considering RF when evaluating the impact of 
the CYP2C9 and CYP1B1 loci on the risk of developing erosive disease. Importantly, when we attempted to vali-
date the RF-specific association of the CYP1B1rs10012G/G genotype with a decreased risk of having erosive disease in 
the replication population, we found that seropositive patients carrying the CYP1B1rs10012G/G genotype had a sig-
nificantly decreased risk of developing bone erosions (ORRF+ = 0.30, P = 0.0051) whereas an opposite but not sig-
nificant effect was found in seronegative patients (ORRF− = 5.97, P = 0.10; PInt = 0.012; Table 4). The meta-analysis 
of both populations confirmed the strong RF-specific effect of this SNP to determine the risk of developing bone 
erosions (ORRF+ = 0.38, P = 0.000081; PHet = 0.52 vs. ORRF− = 2.22, P = 0.11; PHet = 0.31). Although we attempted 
to validate the association of the CYP2C9rs1799853T/T genotype with a decreased risk of having erosive disease, the 
relatively small size of the replication population did not allow us to perform the association analysis according 
to a recessive model of inheritance. However, we found a RF-specific effect on the risk of having erosive disease 
for a neighboring SNP (rs1057910), which suggested a RF-dependent effect of the CYP2C9 locus to modulate 
the risk of erosive disease (ORRF+ = 2.75, P = 0.027 vs. ORRF− = 0.54, P = 0.47; Table 4). The meta-analysis of 
both cohorts confirmed the RF-specific effect of the CYP2C9rs1057910 SNP on the risk of developing bone erosions 
(ORRF+ = 2.68, P = 0.0022 vs. ORRF− = 1.08, P = 0.83; PHet = 0.34; Table 4).
In line with these findings, we also observed an additional RF effect modification of the FcγR3Ars396991 and 
SHBGrs6259 SNPs to determine the risk of having erosions. Seronegative patients carrying the FcγR3Ars396991C 
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allele had a significantly reduced chance of developing bone erosions (OR = 0.45, P = 0.013) whereas an oppo-
site but not significant effect was observed in seropositive patients (OR = 1.18, P = 0.46; PInt = 0.028; Table 3). 
Furthermore, seropositive subjects carrying the SHBGrs6259A allele showed an increased risk of developing bone 
erosions (ORRF+ = 1.87, P = 0.015) whereas an opposite but not significant effect was detected in seronegative 
patients (ORRF− = 0.66, P = 0.19). Interestingly, although the effect was stronger in seronegative patients, we could 
validate the RF-specific effect of the SHBGrs6259 SNP on the risk of developing erosions in the replication popu-
lation (ORRF+ = 1.17, P = 0.63 vs. ORRF− = 0.22, P = 0.009; PInt = 0.013; Table 4) and the meta-analysis of both 
cohorts confirmed that the effect of this marker was dependent on the RF status (ORRF+ = 1.55, P = 0.033 vs. 
ORRF− = 0.48, P = 0.0087; PHet = 0.14; Table 4). Although we could not validate the RF-specific association of 









PInteractionOR (95% CI)† P OR (95% CI)† P OR (95% CI)† P
CYP1A1 rs1799814 A 0.85 (0.52–1.39) 0.52 0.82 (0.43–1.54) 0.53 0.98 (0.44–2.18) 0.96 0.54
CYP1A2 rs762551 C 0.91 (0.66–1.25) 0.57 0.72 (0.48–1.09) 0.12 1.37 (0.80–2.34) 0.25 0.059
CYP1B1 rs1800440 G 1.06 (0.76–1.46) 0.74 1.12 (0.74–1.69) 0.60 0.97 (0.55–1.69) 0.90 0.50
CYP1B1 rs1056836 G 0.92 (0.64–1.32) 0.66 1.04 (0.67–1.63) 0.85 0.66 (0.34–1.26) 0.21 0.35
CYP1B1 rs10012 G 0.62 (0.37–1.04)§ 0.071 0.42 (0.23–0.76)§ 0.004 1.70 (0.56–5.17)§ 0.35 0.031
CYP2C9 rs1799853 T 0.45 (0.20–1.02)§ 0.056 0.16 (0.06–0.46)§ 0.0007 2.71 (0.53–13.8)§ 0.23 0.003
CYP2C9 rs1057910 C 1.68 (0.98–2.89) 0.059 2.63 (1.15–6.03) 0.012 1.28 (0.58–2.81) 0.54 0.20
CYP2C19 rs12248560 T 1.04 (0.75–1.44) 0.83 1.09 (0.72–1.65) 0.70 0.96 (0.54–1.70) 0.89 0.55
CYP2C19 rs4244285 A 1.00 (0.69–1.44) 0.99 1.02 (0.64–1.61) 0.94 0.90 (0.47–1.70) 0.74 0.79
CYP3A4 rs2740574 G 1.57 (0.90–2.74) 0.11 3.12 (1.29–7.55) 0.004 0.70 (0.29–1.66) 0.42 0.021
CYP3A4 rs11773597 C 1.19 (0.77–1.84) 0.43 1.33 (0.74–2.38) 0.35 1.00 (0.50–2.03) 0.99 0.65
CYP17A1 rs743572 G 0.92 (0.66–1.28) 0.63 0.99 (0.65–1.50) 0.97 0.82 (0.46–1.45) 0.49 0.62
ESR1 rs851984 T 1.07 (0.78–1.46) 0.68 0.82 (0.55–1.24) 0.35 1.56 (0.91–2.68) 0.10 0.078
ESR1 rs2881766 G 1.00 (0.72–1.39) 0.99 1.08 (0.71–1.65) 0.71 0.83 (0.47–1.48) 0.54 0.47
ESR1 rs2071454 G 0.96 (0.65–1.42) 0.82 1.06 (0.65–1.75) 0.81 0.75 (0.38–1.49) 0.42 0.41
ESR1 rs2077647 G 0.92 (0.65–1.30) 0.64 0.70 (0.45–1.09) 0.11 1.46 (0.81–2.63) 0.21 0.030
ESR1 rs827421 C 0.95 (0.67–1.33) 0.75 0.80 (0.52–1.25) 0.33 1.21 (0.66–2.20) 0.54 0.18
ESR1 rs2234693 C 1.10 (0.78–1.55) 0.58 0.97 (0.62–1.51) 0.89 1.33 (0.73–2.40) 0.35 0.32
ESR1 rs9340799 G 0.97 (0.71–1.34) 0.87 0.78 (0.52–1.17) 0.23 1.42 (0.82–2.45) 0.21 0.052
ESR1 rs1801132 G 0.71 (0.52–0.97) 0.034 0.85 (0.57–1.27) 0.44 0.53 (0.31–0.92) 0.025 0.13
ESR1 rs3798577 C 1.21 (0.87–1.68) 0.27 1.39 (0.92–2.10) 0.12 1.12 (0.63–2.01) 0.69 0.50
ESR1 rs910416 T 0.84 (0.59–1.19) 0.33 0.75 (0.47–1.18) 0.21 0.91 (0.51–1.61) 0.74 0.68
ESR2 rs1255998 G 0.92 (0.64–1.33) 0.67 1.07 (0.66–1.72) 0.78 0.72 (0.39–1.34) 0.30 0.44
ESR2 rs928554 G 0.78 (0.52–1.17)§ 0.23 0.58 (0.35–0.96)§ 0.035 1.39 (0.70–2.78)§ 0.35 0.032
ESR2 rs4986938 T 1.09 (0.79–1.51) 0.59 1.41 (0.93–2.11) 0.10 0.74 (0.42–1.29) 0.29 0.068
ESR2 rs1271572 T 0.55 (0.37–0.82)§ 0.004 0.38 (0.23–0.63)§ 0.0002 1.08 (0.54–2.14)§ 0.83 0.018
FcγR2A rs1801274 G 1.04 (0.72–1.51) 0.82 1.17 (0.74–1.86) 0.50 0.83 (0.43–1.61) 0.58 0.33
FcγR3A rs396991 C 0.90 (0.64–1.27) 0.56 1.18 (0.76–1.81) 0.46 0.45 (0.24–0.85) 0.013 0.028
GSTP1 rs1695 G 1.05 (0.77–1.44) 0.76 1.16 (0.77–1.75) 0.47 0.70 (0.41–1.21) 0.20 0.26
GSTP1 rs1138272 T 1.32 (0.77–2.25) 0.31 1.70 (0.83–3.46) 0.13 0.71 (0.28–1.77) 0.46 0.24
HSD17B1 rs605059 T 1.12 (0.79–1.59) 0.54 1.24 (0.80–1.92) 0.33 1.12 (0.59–2.12) 0.74 0.82
NR1I2 rs2276706 A 1.01 (0.74–1.40) 0.93 0.96 (0.64–1.43) 0.83 1.18 (0.68–2.06) 0.55 0.47
NR1I2 rs1464603 C 1.16 (0.85–1.59) 0.35 1.14 (0.76–1.69) 0.53 1.45 (0.84–2.49) 0.18 0.54
NR1I2 rs6785049 G 0.92 (0.66–1.27) 0.60 0.95 (0.63–1.43) 0.81 1.03 (0.58–1.84) 0.92 0.93
NR1I2 rs2276707 T 1.03 (0.73–1.45) 0.87 0.80 (0.51–1.23) 0.31 1.62 (0.90–2.89) 0.11 0.064
NR1I2 rs1054191 A 0.83 (0.59–1.17) 0.30 1.02 (0.65–1.58) 0.94 0.58 (0.32–1.06) 0.076 0.12
PGR rs1042838 A 0.76 (0.53–1.08) 0.13 0.74 (0.47–1.15) 0.18 0.86 (0.46–1.62) 0.64 0.99
PGR rs1379130 A 0.92 (0.66–1.26) 0.59 1.02 (0.68–1.53) 0.93 0.79 (0.46–1.37) 0.40 0.59
PGR rs518162 A 1.11 (0.75–1.64) 0.62 1.41 (0.83–2.39) 0.21 0.64 (0.33–1.25) 0.19 0.092
SHBG rs6259 A 1.22 (0.83–1.78) 0.31 1.87 (1.11–3.14) 0.015 0.66 (0.35–1.23) 0.19 0.006
SULT1A1 rs9282861 A 1.04 (0.76–1.43) 0.79 0.86 (0.58–1.29) 0.46 1.38 (0.80–2.39) 0.25 0.13
Table 3. Overall and RF-specific associations of estrogen-related polymorphisms and risk of developing erosive 
disease. Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. Data 
on RF was available in 809 RA patients. Estimates were adjusted for age, sex and country of origin. P < 0.05 in 
bold. †Estimates calculated according to a dominant model of inheritance. §Estimates calculated according to a 
recessive model of inheritance.
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the RF-specific effect of this SNP to modulate the risk of developing erosive disease (ORRF− = 0.47, P = 0.0067 
vs. ORRF+ = 1.02, P = 0.93). None of these two SNPs showed a significant effect modification by anti-CCP 
(PInt = 0.85) suggesting again that RF, rather than anti-CCP, is a driver factor influencing the impact of the steroid 
hormone-related loci on disease progression in RA.
Finally, an overall association analysis revealed that carriers of the ESR1rs1801132G allele showed a decreased 
risk of developing bone erosions (OR = 0.71, P = 0.034). Although we could not validate this association in the 
replication population, we found that this SNP showed a significant RF-specific effect to modulate the risk of 
developing bone erosions but according to a recessive model of inheritance. Thus, seropositive carriers of the 
ESR1rs1801132G/G genotype showed a decreased risk of developing bone erosions (ORRF+ = 0.39, P = 0.004) whereas 
an opposite but not statistically significant effect was observed in seronegative subjects (ORRF− = 1.43, P = 0.57; 
Table 4). Furthermore, we found a similar RF-specific effect for the ESR1rs9340799 SNP that was not detected in 
the discovery population (ORRF+ = 0.42, P = 0.009 vs ORRF− = 8.33, P = 0.011). Considering that none of these 
associations survived after correction for multiple testing and that the effect of ESR1 SNPs on the risk of devel-
oping erosive disease seemed to depend on the inheritance model applied, these results suggested a complex 
relationship between the ESR1 locus and bone erosion probably mediated by more than one SNP. In support of 
this notion, we found that 3 large ESR1 haplotypes (ESR1CTATTTTCTA, ESR1CTATTCTTCA, and ESR1GTATTCTCTA) were 
significantly associated with a decreased risk of having erosive disease (P = 0.0094, P = 0.0021 and P = 0.0023, 
respectively; Supplementary Table 2).
correlation of selected Snps with steroid hormone levels. Besides the strong genetic association 
with erosive disease identified for the CYP2C9rs1799853 SNP and its known role in controlling the metabolism of 
a wide range of drugs (with the T allele acting as poor metabolizer), we found that this coding variant strongly 
correlated with serum vitamin D3 levels in women (P = 0.00085 and P = 0.0019; Fig. 1) whereas no effect was 
detected in men. Although the association of the CYP2C9rs1799853 SNP with reduced levels of vitamin D3 in 
women remained borderline significant, this finding suggested that this marker might have a role in the modula-
tion of bone homeostasis and vitamin D3-mediated immune responses.
On the other hand, we found that the ESR1rs2881766G/G genotype or G allele weakly correlated with progesterone 
levels (P = 0.0076 and P = 0.0071) and that the ESR1rs851984, ESR1rs2077647, ESR1rs2071454, ESR1rs3798577 and ESR1rs910416 
variants mapped among histone marks in several cell types including osteoblasts and a wide variety of immune 
cells.
correlation of steroid hormone Snps with cytokine levels. Interestingly, we also found that carriers 
of the ESR2rs4986938T allele had reduced levels of TNFα after the stimulation of PBMCs with Pam3Cys for 24 h 
(P = 0.0022; Fig. 2A). These results along with those reporting that the ESR2rs4986938 and ESR2rs1271572 SNPs map 
among histone marks in multiple cell types including osteoblasts and different subsets of immune cells, suggest 
a possible functional role of the ESR2 variants in modulating the risk of developing bone erosions likely through 
the modulation of ESR2 expression. In addition, we found that the presence of the CYP2C9rs1799853T allele cor-
related with an increased production of IL1β after the stimulation of PBMCs with LPS or PHA for 24 h or 48 h 
(P = 0.0057 and P = 0.0058; Fig. 2B,C), which also pointed to a functional role of this marker in determining the 
presence of bone erosions.
In addition, we found that the ESR1rs3798577 variant correlated with TNFα and IL6 levels after the stimulation of 
human macrophages with LPS for 24 h (P = 0.00083 and 0.0011; Fig. 2D,E). Finally, we found that carriers of the 
FcγR3Ars396991C allele showed a significantly increased production of TNFα after stimulation of macrophages with 
LPS for 24 h (P = 1.97•10−7; Fig. 2F). Of note, the association of the FcγR3Ars396991C allele with increased levels of 
TNFα in macrophages survived after correction for multiple testing, which strongly suggested a functional effect 
of this variant to modulate macrophage-mediated immune responses, a key factor influencing the risk of develop-
ing erosive disease. On the contrary, although it was tempting to speculate that ESR1, ESR2, CYP2C9 SNPs might 
also exert their effect on the risk of developing erosive disease through the modulation of steroid hormones or 
steroid hormone-mediated immune responses, it is important to mention that none of the associations between 
ESR1, ESR2 or CYP2C9 SNPs and cytokine levels survived after correction for multiple testing, which suggested a 
modest functional impact of these polymorphisms on the risk of developing bone erosions.
Usefulness of steroid hormone-related Snps to predict erosive disease. As a whole, our data sug-
gest that the attributable effect of the CYP1B1, CYP2C9, ESR1, ESR2, SHBG, and FcγR3A loci to modulate the risk 
of developing bone erosions in RA patients might be dependent on the presence of either missense or intronic 
polymorphisms that affect the immune responses to a greater or lesser extent. Considering the strength of the 
RF-specific associations found for SNPs within CYP1B1, CYP2C9, SHBG, ESR1, ESR2, FcγR3A and CYP3A4 loci 
in the discovery and/or replication populations, we decided to assess whether SNPs within these loci could be 
useful to differentially predict disease progression in seropositive and seronegative patients. Our results showed 
that the addition of 5 steroid hormone-related SNPs within the CYP1B1, CYP2C9, CYP3A4, ESR2 and SHBG 
loci to a model including demographic variables significantly improved the ability to predict the appearance 
of bone erosions in seropositive patients (AUCGenetic = 0.73 vs. AUCDemographic = 0.63; P = 2.46•10−8; Table 5) 
whereas no significant predictive value was found for these SNPs in seronegative patients (AUCGenetic = 0.61 vs. 
AUCDemographic = 0.59; P = 0.36; Fig. 3). The consistency of this predictive analysis was confirmed through a per-
mutation test that showed that none of the 50.000 permuted models for each group showed a better prediction 
capacity than the genetic model (Average sorted AUC = 0.644, Z-score = 6.79 and PZ_score (50.000perm) = 5.67•10−12). 
Even though the lack of patients carrying the CYP2C9rs1799853T/T genotype and the relatively small size of the 
replication population hampered the validation of this 5-SNP model to predict erosive disease, we attempted 
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to confirm the utility of this model in the DREAM registry. We found that a similar model slightly improved 
the ability to predict erosive disease in both seropositive and seronegative patients (AUCGenetic-RF+ = 0.63 vs. 
AUCDemographic-RF+ = 0.53; P = 0.014 and AUCGenetic-RF− = 0.78 vs. AUCDemographic-RF− = 0.54; P = 0.015; Fig. 3). 
Despite these interesting results, only the CYP1B1 and CYP2C9 SNPs seemed to have a consistent predictive 
value for the development of bone erosions in seropositive patients.
Discussion
The present study reports, for the first time, both overall and RF-specific associations of steroid hormone-related 
polymorphisms with the risk of developing erosive RA. The most relevant effect was found for SNPs within 
CYP1B1, CYP2C9, and ESR2 genes. We observed that seropositive RA patients carrying the CYP1B1rs10012G/G, 
CYP2C9rs1799853T/T, and ESR2rs1271572T/T, genotypes had a significantly reduced risk of developing bone erosions 
during the course of the disease whereas an opposite but not significant effect was found in seronegative patients. 
Although the relatively small size of the replication population hampered the validation of these associations 
according to a recessive model of inheritance, we could validate the RF-specific association of the CYP1B1rs10012 
SNP with the risk of developing erosive disease in the replication population and the meta-analysis of the dis-
covery and replication cohorts confirmed the strong RF effect modification of this SNP to determine the risk 
of bone erosions. In addition, although we could not validate the RF-specific association of the CYP2C9rs1799853 
variant in the replication population due to the lack of patients carrying the CYP2C9rs1799853T/T genotype, we 
found a RF-specific effect on the risk of having erosive disease for a neighbouring SNP within the CYP2C9 locus 
(rs1057910) that was further confirmed through meta-analysis. Although this SNP was not in linkage disequilib-
rium (LD) with the rs1799853 and, therefore, does not represent the same association signal, these results support 
the idea that the CYP2C9 locus might influence the risk of developing bone erosions in a RF dependent manner 
and likely through the modulation of the hormone metabolism and hormone-dependent immune responses.
Whilst the CYP1B1 locus is located on chromosome 2p21-22, CYP2C9 belongs to the CYP2C family, a gene 
cluster (CYP2C19-CYP2C9-CYP2C8) located on chromosome 10q23.3. Together with CYP1A2 and CYP3A4, 
Gene SNP ID Effect allele
DREAM registry Overall 
(n = 436)
DREAM registry RF-positive 
patients (n = 328)
DREAM registry RF-
negative patients (n = 94)
PInteractionOR (95% CI)† P OR (95% CI)† P OR (95% CI)† P
CYP1B1 rs10012 G 0.53 (0.27–1.06)§ 0.073 0.30 (0.13–0.70)§ 0.0051 5.97 (0.70–50.6)§ 0.10 0.012
CYP2C9 rs1799853 T NA (NA-NA)§ NA NA (NA-NA)§ NA NA (NA-NA)§ NA NA
CYP2C9 rs1057910 C 1.89 (0.85–4.22) 0.095 2.75 (1.03–7.35) 0.027 0.54 (0.11–2.72) 0.47 0.073
CYP3A4 rs2740574 G 0.36 (0.17–0.77) 0.008 0.42 (0.17–1.07) 0.075 0.30 (0.08–1.22) 0.098 0.58
ESR1 rs1801132 G 0.54 (0.31–0.96)§ 0.035 0.39 (0.20–0.76)§ 0.004 1.43 (0.40–5.09)§ 0.57 0.065
ESR1 rs9340799 G 0.69 (0.39–1.25)§ 0.23 0.42 (0.22–0.83)§ 0.009 8.33 (1.02–67.8)§ 0.011 0.008
ESR2 rs1255998 G 2.08 (1.17–3.69) 0.009 1.82 (0.94–3.54) 0.065 5.41 (1.15–25.4) 0.012 0.19
ESR2 rs928554 G 0.61 (0.37–1.00) 0.050 0.59 (0.33–1.07) 0.075 0.51 (0.17–1.56) 0.22 0.79
ESR2 rs1271572 T 0.90 (0.56–1.47)§ 0.68 0.78 (0.46–1.37)§ 0.41 2.16 (0.64–7.27)§ 0.19 0.32
FcγR3A rs396991 C 0.74 (0.45–1.22) 0.25 0.78 (0.44–1.40) 0.41 0.53 (0.18–1.62) 0.27 0.58
SHBG rs6259 A 0.86 (0.51–1.47) 0.59 1.17 (0.62–2.20) 0.63 0.22 (0.07–0.71) 0.009 0.013
Gene SNP ID Effect allele
REPAIR + DREAM registry 
Meta-analysis Overall 
(n = 1252) PHet
REPAIR + DREAM registry RF-
positive patients (n = 899) PHet
REPAIR + DREAM registry 
RF-negative patients 
(n = 332) PHet
OR (95% CI)† P OR (95% CI)† P OR (95% CI)† P
CYP1B1 rs10012 G 0.59 (0.39–0.88)§ 0.011 0.72 0.38 (0.23–0.61)§ 0.000081 0.52 2.22 (0.83–5.95)§ 0.11 0.31
CYP2C9 rs1799853 T NA (NA-NA)§ NA NA NA (NA-NA)§ NA NA NA (NA-NA)§ NA NA
CYP2C9 rs1057910 C 1.74 (1.11–2.73) 0.015 0.81 2.68 (1.42–5.048) 0.0022 0.95 1.08 (0.53–2.20) 0.83 0.34
CYP3A4 rs2740574 G 0.94 (0.60–1.46) 0.77 0.002 1.19 (0.63–2.25) 0.59 0.002 0.55 (0.26–1.14) 0.11 0.30
ESR1 rs1801132 G 0.75 (0.58–0.97) 0.030 0.52 0.78 (0.60–1.08) 0.13 0.51 0.72 (0.44–1.17) 0.19 0.02
ESR1 rs9340799 G 0.90 (0.68–1.19) 0.45 0.31 0.73 (0.53–1.00) 0.050 0.61 1.61 (1.00–2.58) 0.048 0.38
ESR2 rs1255998 G 1.16 (0.86–1.59) 0.33 0.02 1.28 (0.87–1.89) 0.20 0.20 0.95 (0.54–1.68) 0.86 0.02
ESR2 rs928554 G 0.70 (0.53–0.93) 0.013 0.50 0.64 (0.45–0.90) 0.013 0.73 0.77 (0.47–1.27) 0.31 0.41
ESR2 rs1271572 T 0.67 (0.49–0.91) 0.011 0.12 0.52 (0.36–0.76)§ 0.00074 0.06 1.28 (0.70–2.33)§ 0.42 0.33
FcγR3A rs396991 C 0.85 (0.64–1.12) 0.24 0.53 1.02 (0.72–1.44) 0.93 0.26 0.47 (0.27–0.81) 0.0067 0.80
SHBG rs6259 A 1.08 (0.79–1.48) 0.62 0.29 1.55 (1.03–2.31) 0.033 0.26 0.48 (0.28–0.83) 0.0087 0.14
Table 4. Replication of the most interesting associations between estrogen-related polymorphisms and risk 
of developing erosive disease (DREAM registry) and meta-analysis. Abbreviations: SNP, single nucleotide 
polymorphism; OR, odds ratio; CI, confidence interval. Data on RF was available in 422 RA patients in 
the replication population. Estimates were adjusted for age and sex. P ≤ 0.05 in bold. The RF-specific effect 
modification of steroid hormone SNPs was determined by logistic regression using RF as interaction term. 
Meta-analysis was conducted following a fixed effect model. †Estimates calculated according to a dominant 
model of inheritance. §Estimates calculated according to a recessive model of inheritance.
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CYP1B1 and CYP2C9 catalyze the conversion of estrogens to genotoxic catechol estrogens (estradiol 4- and 
2-hydroxylation, respectively)53, which are key processes that allow the binding of catechol estrogens to ESR1 
and ESR2. At low concentrations, CYP2C9 is also implicated in the 17beta-hydroxy dehydrogenation of estra-
diol creating estrone, which is one of the 3 natural estrogens with multiple immunomodulatory actions. Given 
that both the CYP1B1rs10012 and CYP2C9rs1799853 SNPs are coding variants that alters their respective protein 
amino acid sequences (R48G and Arg144Cys) and appear to decrease the activity of the enzyme but also proper 
folding and stability, it seems to be plausible to hypothesize that the presence of these SNPs could determinate 
estrogen-dependent immune responses and thereby modulate the risk of developing bone erosions. Our func-
tional studies also demonstrated that the CYP2C9rs1799853 SNP correlated with serum vitamin D3 levels, which 
suggest that the CYP2C9rs1799853 SNP might also affect disease progression through the regulation of vitamin 
D3-mediated immune responses. However, we need to interpret these results with caution as we only found a 
significant correlation with vitamin D3 in women whereas no effect was seen in men. These results, together 
with those reporting that carriers of the CYP2C9rs1799853T allele have an increased production of IL1β after the 
stimulation of PBMCs or whole blood with LPS or PHA, suggest that the protective effect attributed to this 
coding variant might not only depend on vitamin D3 but other factors such as RF or even other stimuli or sub-
strates. In this regard, our team has reported that the CYP2C9rs1799853 polymorphism is strongly associated with 
poor response to anti-TNF drugs in RA54, suggesting that this missense variant might modulate the strength of 
immune responses through the regulation of the metabolism of endogenous compounds but also compounds 
administered exogenously.
Although we also attempted to validate the RF-specific association of the ESR2rs1271572T/T genotype with a 
decreased risk of having erosion in the replication population, we only found a modest and not significant effect 
of this variant to determine erosive disease. However, the direction of the effect in seropositive and seronega-
tive patients was similar to the one observed in the discovery population and the meta-analysis of both cohorts 
confirmed that the effect of this SNP on the risk of developing bone erosions was modified by RF. In support 
of a RF-specific effect of this variant to influence the risk of erosive RA, we found that seropositive carriers of 
the ESR2CGTA haplotype had a decreased risk to develop erosive RA whereas no effect was detected in seroneg-
ative patients. Interestingly, an overall haplotype analysis also revealed a significant association of 3 common 
Figure 1. Correlation of the CYP2C9rs1799853 and ESR1rs2881766 SNPs with vitamin D3 and progesterone levels in 
women (n = 107) and men (n = 172). Patients using oral contraceptives were excluded from the analysis. After 
log transformation, linear regression analyses were adjusted for age. NS; non-significant.
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haplotypes within the ESR1 locus (ESR1CTATTTTCTA, ESR1CTATTCTTCA, and ESR1GTATTCTCTA) with a decreased risk of 
developing bone erosions, which also pointed to a role of ESR1 SNPs in modulating the risk of erosions.
The ESR2 and ESR1 genes (14q23.2 and 6q25.1 respectively) encode the estrogen receptor beta (ESRβ) and 
alpha (ESRα) that are highly expressed in synovial cells55 and bone56 but also in most of the immune cells57. 
Although a number of experimental studies have shown that female RA patients have worse prognosis and 
higher disease activity and health assessment questionnaire scores in comparison with male patients, it is also 
well established that steroid hormones have both pro- and anti-inflammatory roles in RA. Although it has been 
reported, for instance, that the activation of ESRs by estradiol (E2) often leads to joint protection and the mainte-
nance of bone density (by inhibiting bone resorption)58 and that the withdrawal of estrogens drastically increases 
the severity of the disease (by promoting joint destruction, bone erosions and physical disability)59, it has been 
also reported that RA patients have high levels of estrone in the synovial fluid compared to healthy individuals 
and that estrogens can also induce pro-inflammatory responses through the activation of different mechanisms 
involving humoral immunity60, multiple transcription factors (such as c/EBPβ, STAT-1, NFκB) and oxidative 
stress pathways (especially those involving iNOs)61,62. Furthermore, it has been reported that estrogens are able 
to promote pro-inflammatory pathways including B- and T-cell proliferation63, thymocyte maturation64, cell traf-
ficking65 and the expression of specific adhesion molecules63. Although the existing paradox with respect to the 
immunomodulating role of steroid hormones in RA remain unresolved, it seems to be reasonable to hypothesize 
that the presence of ESR2 polymorphisms that correlate either with ESR2 mRNA expression levels may influence 
on the risk of developing bone erosions in RA likely through the modulation of ESR2-dependent tolerogenic 
immune responses. In addition, although the association of the ESR2 and ESR1 polymorphisms with serum 
hormone levels or TNF and IL6 levels in stimulated macrophages did not remain significant after correction for 
multiple testing, our functional findings were in agreement with the genetic results suggesting a protective effect 
of ESR2 polymorphisms and specific ESR1 haplotypes on the risk of developing erosive RA. In addition, our 
genetic and functional results were also concordant with data of previous studies reporting that the presence of 
certain SNPs, microsatellites or even specific haplotypes within estrogen receptor genes is associated with bone 
mineral density and influences the risk of developing bone erosions66,67 affecting RA patients68 but also subjects 
diagnosed with other chronic inflammatory diseases69 and bone degenerative diseases70,71.
Finally, this study also showed a weak but still interesting RF-specific effect of the SHBGrs6259 and FcγR3Ars396991 
SNPs to determine the risk of having erosions. Importantly, we could validate the RF-specific effect of the 
SHBGrs6259 SNP on the risk of developing erosions in the replication population and the meta-analysis of both 
cohorts confirmed that the effect of this marker was strongly dependent on the RF status. On the other hand, 
Figure 2. Correlation of hormone-related SNPs with cytokine levels after stimulation of PBMCs or 
macrophages with LPS, PHA or Pam3Cys (n = 408).
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although the RF-specific association of the FcγR3Ars396991 SNP with bone erosions was not statistically significant 
in the DREAM registry, the meta-analysis of both cohorts confirmed that the effect of this SNP on the risk of bone 
erosions was modified by the RF.
Whereas little is known about the role of the SHBG locus (17p13) in determining RA progression, a number of 
experimental studies have shown that the FcγR3A locus (1q23) is involved in the recognition of IgG1 and IgG3 by 
NK cells and macrophages and that the activation of this receptor by IgG and IgG-RF immunocomplexes might 
lead to the initiation of a range of sustained and harmful inflammation events that, if chronified, may cause joint 
and bone destruction and promote the onset of RA72–74. In this context and considering the number of studies 
reporting association of the FcγR3Ars396991 SNP with autoimmune diseases75–82, the response to a wide range of 
biologic drugs83–89 and an exacerbated production of TNFα after stimulation of macrophages with LPS for 24 h 
but also the reported association of the SHBGrs6259 with serum SHBG levels90, we hypothesize that these SNPs 
might also play a relevant role in determining bone erosions and disease progression.
Considering the noticeable RF-specific impact of the CYP1B1, CYP2C9, ESR2, FcγR3A and SHBG SNPs on 
the risk of developing erosive disease but also their functional implication in modulating hormone levels and/
or immune responses, we decided to assess if the presence of steroid hormone-related SNPs could be useful to 
reliably predict the appearance of bone erosions in seropositive and seronegative patients separately. To do that, 
we built a genetic model including demographic variables and those SNPs that were consistently associated with 
the risk of developing bone erosions in seropositive patients. After removing the SNPs that were not significantly 
associated with erosive disease in the model, we obtained a model including 5 SNPs within the CYP1B1, CYP2C9, 
CYP3A4, ESR2, and SHBG loci that significantly improved the ability to predict the risk of developing erosive 
disease when compared with a reference model including demographic variables. The predictive capacity of these 
SNPs was restricted to seropositive patients since the addition of the same SNPs (or any other genetic marker) to a 
model built with demographic variables in seronegative patients did not show any predictive value. The predictive 
Discovery population (REPAIR Consortium; n = 816; RF += 571 and RF− = 238) Replication population (DREAM registry; n = 436; RF += 328 and RF− = 94)
Demographic model (RF + Patients; n = 460)
LR test 
p-value Demographic model (RF + Patients; n = 242)
LR test 
p-value
P-value OR 95%CI AUC 95%CIa P-value OR 95%CI AUC 95%CIa
Gender (male) 0.004 0.486 (0.296–0.798) Gender (male) 0.740 1.113 (0.590–2.100)
Age 0.00066 1.030 (1.013–1.048) 0.629 (0.567–0.692) Age 0.654 0.995 (0.972–1.018) 0.528 (0.445–0.612)
Predictive model including 5 SNPs (RF + patients; n = 460)* Predictive model including 4 SNPs (RF + patients; n = 242)Ϯ
P-value OR 95%CI AUC 95%CIa P-value OR 95%CI AUC 95%CIa
ESR2rs1271572 0.002 0.414 (0.236–0.726) 0.730 (0.672–0.780)‡ ESR2rs1271572 0.763 0.899 (0.450–1.796) 0.625 (0.541–0.709)
CYP2C9rs1799853 0.024 0.226 (0.062–0.824) CYP2C9rs1057910 0.058 3.385 (0.96–11.94)
CYP1B1rs10012 0.013 0.442 (0.233–0.840) CYP1B1rs10012 0.014 0.285 (0.105–0.772)
CYP3A4rs2740574 0.005 5.793 (1.718–19.53) CYP3A4rs2740574 0.075 0.370 (0.124–1.107)
SHBGr6259 0.011 2.316 (1.212–4.425) SHBGr6259 0.444 1.378 (0.606–3.130)
Gender (male) 0.005 0.475 (0.281–0.803) Gender (male) 0.941 0.976 (0.505–1.884)
Age 0.00039 1.033 (1.015–1.052) 2.46•10–8 Age 0.811 0.997 (0.972–1.022) 0.014
Demographic model (RF− patients; n = 182) LR test p-value Demographic model (RF− patients; n = 64)
LR test 
p-value
P-value OR 95%CI AUC 95%CIa P-value OR 95%CI AUC 95%CIa
Gender (male) 0.713 0.864 (0.397–1.882) Gender (male) 0.322 0.542 (0.161–1.820)
Age 0.053 0.978 (0.956–1.000) 0.588 (0.503–0.672) Age 0.511 1.014 (0.973–1.056) 0.590 (0.429–0.752)
Predictive model including 5 SNPs (RF− patients; n = 182) Predictive model including 4 SNPs (RF− patients; n = 64)Ϯ
P-value OR 95%CI AUC 95%CIa P-value OR 95%CI AUC 95%CIa
ESR2rs1271572 0.804 1.103 (0.509–2.388) 0.613 (0.530–0.696) ESR2rs1271572 0.828 1.214 (0.212–6.937) 0.778 (0.640–0.917)
CYP2C9rs1799853 0.105 6.052 (0.688–53.26) CYP2C9rs1057910 0.219 0.287 (0.039–2.097)
CYP1B1rs10012 0.521 1.526 (0.420–5.549) CYP1B1rs10012 0.493 2.316 (0.209–25.60)
CYP3A4rs2740574 0.422 0.668 (0.250–1.785) CYP3A4rs2740574 0.033 0.113 (0.015–0.836)
SHBGr6259 0.699 0.870 (0.43–1.760) SHBGr6259 0.029 0.139 (0.024–0.814)
Gender (male) 0.394 0.696 (0.303–1.600) Gender (male) 0.287 0.453 (0.106–1.943)
Age 0.065 0.979 (0.956–1.001) 0.36 Age 0.949 0.998 (0.950–1.049) 0.015
Table 5. Discriminative value AUC for the model including estrogen-related variants in the discovery and 
replication populations. aIncluding age and gender as variables never dropped from models and when are 
compared with a baseline model with AUROC = 0.5. P ≤ 0.10 in bold (stepwise threshold). *All SNPs showing 
a significant association with erosive disease (P < 0.10) were initially added to the model in the discovery 
population. ‡A sort analysis in the discovery population revealed that this model showed an AUC value 
systematically higher than those observed in 50.000 randomized models: Average AUC of null distribution 
(50.000 models) = 0.644 Z score = 6.79, PZ_score-value_(50.000perm) = 5.67•10−12. ϮAll SNPs were forced to be 
included in the replication population with the exception of the CYP2C9rs1057910 that was included due to the 
impossibility to calculate association estimates for the CYP2C9rs1799853 SNP.
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ability of the genetic model in seropositive patients was consistent as no similar models were found after perform-
ing a 50.000 permutation test. When we attempted to confirm the utility of this model in the DREAM registry, 
we found that the CYP1B1 and CYP2C9 SNPs in seropositive patients showed a consistent predictive value for 
the development of bone erosions. These results suggest that CYP1B1 and CYP2C9 SNPs alone or in combina-
tion with other clinical and genetic markers might help to improve the ability to predict the appearance of bone 
erosions in seropositive patients (~70% of RA patients). Additional studies including these and other genetic and 
clinical markers are urgently needed to improve our ability to predict disease progression in RA.
This study has strengths and weaknesses. The strengths of this study include a relatively large and 
well-characterized population and the meta-analyses conducted considering results from the DREAM registry. 
In the discovery population, we had 80% of power to detect an odds ratio of 1.68 (α = 0.00074) for a SNP with a 
frequency of 0.25, which underlined the feasibility of the study design. Another important strength of this study 
is the development of cytokine stimulation experiments and the measurement of seven serum steroid hormones 
in a large cohort of healthy subjects, which allowed us to investigate the functional role of the most interesting 
markers in modulating immune responses but also to test their impact on determining steroid hormone levels. 
A drawback is the multicenter nature of this study that placed inevitable limitations such as the impossibility of 
using available scores to better define bone erosions (Sharp van der Heijde, Genant, SENSE, and Ratingen scores). 
Given the cross-sectional approach of the study, we had also intrinsic limitations such as a possible bias due to 
variations in treatments and follow-up time among study participants. Finally, it is important to mention that the 
selection of SNPs for this study was influenced by the limited research funds and that the relatively small size of 
Figure 3. Receiver operating characteristics (ROC) curve analysis in the discovery and replication populations. 
ROC curves summarize the accuracy of prediction for genetic and demographic models in seropositive and 
seronegative patients. The genetic models (marked in blue) included SNPs that were significantly associated 
with erosive disease in seropositive patients (either in the single-SNP or haplotype analyses) whereas the 
demographic models included demographic variables (age and gender as covariates; marked in green) for 
seropositive and seronegative patients.
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the replication population hampered the validation of the most interesting associations that were detected when 
a recessive model of inheritance was assumed.
conclusion
In conclusion, this candidate gene association study suggests, for the first time, that the presence of CYP1B1, 
CYP2C9, ESR1, ESR2, SHBG and FcγR3A SNPs or haplotypes influence the risk of developing bone erosions in 
RA. This study also shows that the effect found for most of the SNPs or haplotypes was dependent on the RF status 
and that genotyping of hormone-related SNPs might help to reliably predict disease progression in seropositive 
patients.
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